Perhaps this effect is negligible in some cancer contexts, but because we show that HDAC inhibitors contribute to the overexpression of MMP-9, HDAC inhibitors may also have the capability of enriching a subpopulation of highly metastatic cancer cells especially if a few of the cancer cells escape being eliminated in the first rounds of chemotherapy. The gene discussed is MMP9; the disease is cancer.